Literature DB >> 12364440

Chromosomal aberrations by comparative genomic hybridization in hürthle cell thyroid carcinomas are associated with tumor recurrence.

Nobuyuki Wada1, Quan-Yang Duh, Daishu Miura, Laurent Brunaud, Mariwil G Wong, Orlo H Clark.   

Abstract

Hürthle cell thyroid neoplasms are classified as variants of follicular neoplasms, but they have distinct clinicopathological features. Chromosomal aberrations by comparative genomic hybridization (CGH) are common in Hürthle cell neoplasms. However, there is currently only limited information concerning the relationship between the chromosomal aberrations by CGH and tumor behavior. We, therefore, investigated chromosomal aberrations in primary Hürthle cell neoplasms (13 carcinomas and 15 adenomas) using CGH and correlated the aberrations identified with tumor node metastasis (TNM) stage, tumor differentiation, capsular invasion, and tumor recurrence. Chromosomal aberrations were found in 62% (8 of 13) of carcinomas and 60% (9 of 15) of adenomas. Overall, common chromosomal gains were found on 5p (29%), 5q (36%), 7 (29%), 12p (14%), 12q (21%), 17p (29%), 17q (32%), 19p (32%), 19q (25%), 20p (21%), 20q (29%), and 22q (18%). Common chromosomal losses were found on 2q (18%) and 9q (18%). Thirty-eight percent (5 of 13) of carcinomas were TNM stage III, 31% (4 of 13) were moderately to poorly differentiated, and 46% (6 of 13) were intermediately to widely invasive. Recurrence occurred in 38% (5 of 13). Carcinomas that subsequently recurred had a greater number of chromosomal gains (9.0 vs. 1.3; <0.005) and had more frequent chromosomal gains on 12q, 19q, and 20p (<0.001), 5p, 7, 19p, and 20q (<0.005), and 12p (<0.01) than those that did not recur. Five of the eight (63%) patients with aberrations developed recurrence, whereas none of the five patients without aberrations developed recurrence. In conclusion, chromosomal gains by CGH on 5p, 7, 12p, 12q, 19p, 19q, 20p, and 20q in Hürthle cell carcinomas are associated with tumor recurrence. Such chromosomal aberrations may be predictive for recurrent disease in patients with Hürthle cell thyroid carcinoma.

Entities:  

Mesh:

Year:  2002        PMID: 12364440     DOI: 10.1210/jc.2002-020339

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants.

Authors:  Ivana Kurelac; Dario de Biase; Claudia Calabrese; Claudio Ceccarelli; Charlotte Ky Ng; Raymond Lim; Alan MacKay; Britta Weigelt; Anna Maria Porcelli; Jorge S Reis-Filho; Giovanni Tallini; Giuseppe Gasparre
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

Review 2.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

3.  Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization.

Authors:  Leonard Da Silva; Daniel James; Peter T Simpson; Daniel Walker; Ana Cristina Vargas; Janani Jayanthan; Sunil R Lakhani; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

Review 4.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

Review 5.  Prognostic indications for Hürthle cell cancer.

Authors:  Yevgeniya Kushchayeva; Quan-Yang Duh; Electron Kebebew; Orlo H Clark
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

6.  Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features.

Authors:  Bin Xu; Ed Reznik; R Michael Tuttle; Jeffrey Knauf; James A Fagin; Nora Katabi; Snjezana Dogan; Nathaniel Aleynick; Venkatraman Seshan; Sumit Middha; Danny Enepekides; Gian Piero Casadei; Erica Solaroli; Giovanni Tallini; Ronald Ghossein; Ian Ganly
Journal:  Endocrine       Date:  2019-01-28       Impact factor: 3.633

7.  Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.

Authors:  Rebecca S Sippel; Dina M Elaraj; Elham Khanafshar; Rasa Zarnegar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

8.  Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Authors:  Raj K Gopal; Kirsten Kübler; Sarah E Calvo; Paz Polak; Dimitri Livitz; Daniel Rosebrock; Peter M Sadow; Braidie Campbell; Samuel E Donovan; Salma Amin; Benjamin J Gigliotti; Zenon Grabarek; Julian M Hess; Chip Stewart; Lior Z Braunstein; Peter F Arndt; Scott Mordecai; Angela R Shih; Frances Chaves; Tiannan Zhan; Carrie C Lubitz; Jiwoong Kim; A John Iafrate; Lori Wirth; Sareh Parangi; Ignaty Leshchiner; Gilbert H Daniels; Vamsi K Mootha; Dora Dias-Santagata; Gad Getz; David G McFadden
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

9.  Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma.

Authors:  Willem E Corver; Dina Ruano; Karin Weijers; Wietske C E den Hartog; Merlijn P van Nieuwenhuizen; Noel de Miranda; Ronald van Eijk; Anneke Middeldorp; Ekaterina S Jordanova; Jan Oosting; Ellen Kapiteijn; Guido Hovens; Jan Smit; Tom van Wezel; Hans Morreau
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.